Last reviewed 2026-04-23 · How we verify

Docetaxel-PM

Docetaxel-PM is a taxane chemotherapy medication that works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells.

Docetaxel-PM is a taxane chemotherapy medication that works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer.

At a glance

Mechanism of action

Docetaxel-PM binds to tubulin and promotes the assembly of microtubules, leading to the stabilization of microtubules and the inhibition of cell division. This results in the induction of apoptosis in rapidly dividing cancer cells.

Approved indications

• Non-small cell lung cancer
• Breast cancer

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Fatigue
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Mucositis
• Alopecia

Key clinical trials

• A Phase I Study of SIM0388 in Participants With Malignant Ascites. (PHASE1)
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer (PHASE2)
• A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors (PHASE2)
• Study to Evaluate the Safety of Nanoxel M Inj.
• A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients (PHASE2)
• Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC (PHASE3)
• A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer (PHASE2)
• Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.